GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (NAS:RCEL) » Definitions » Cyclically Adjusted PS Ratio

AVITA Medical (AVITA Medical) Cyclically Adjusted PS Ratio : 6.56 (As of Jun. 06, 2024)


View and export this data going back to 2012. Start your Free Trial

What is AVITA Medical Cyclically Adjusted PS Ratio?

As of today (2024-06-06), AVITA Medical's current share price is $9.51. AVITA Medical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.45. AVITA Medical's Cyclically Adjusted PS Ratio for today is 6.56.

The historical rank and industry rank for AVITA Medical's Cyclically Adjusted PS Ratio or its related term are showing as below:

RCEL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.84   Med: 12.86   Max: 79.78
Current: 6.09

During the past years, AVITA Medical's highest Cyclically Adjusted PS Ratio was 79.78. The lowest was 3.84. And the median was 12.86.

RCEL's Cyclically Adjusted PS Ratio is ranked worse than
75.68% of 477 companies
in the Medical Devices & Instruments industry
Industry Median: 2.15 vs RCEL: 6.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AVITA Medical's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.433. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.45 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AVITA Medical Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AVITA Medical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Cyclically Adjusted PS Ratio Chart

AVITA Medical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 43.44 20.08 5.47 9.73

AVITA Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.12 13.01 10.69 9.73 11.04

Competitive Comparison of AVITA Medical's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, AVITA Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Cyclically Adjusted PS Ratio falls into.



AVITA Medical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AVITA Medical's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=9.51/1.45
=6.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVITA Medical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AVITA Medical's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.433/131.7762*131.7762
=0.433

Current CPI (Mar. 2024) = 131.7762.

AVITA Medical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.174 108.329 0.212
201912 0.164 108.420 0.199
202003 0.183 108.902 0.221
202006 0.181 108.767 0.219
202009 0.235 109.815 0.282
202012 0.236 109.897 0.283
202103 0.386 111.754 0.455
202106 0.415 114.631 0.477
202109 0.282 115.734 0.321
202112 0.278 117.630 0.311
202203 0.302 121.301 0.328
202206 0.334 125.017 0.352
202209 0.364 125.227 0.383
202212 0.377 125.222 0.397
202303 0.419 127.348 0.434
202306 0.466 128.729 0.477
202309 0.537 129.860 0.545
202312 0.557 129.419 0.567
202403 0.433 131.776 0.433

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVITA Medical  (NAS:RCEL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AVITA Medical Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVITA Medical (AVITA Medical) Business Description

Address
28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Executives
James Corbett director 2 GOODYEAR, IRVINE CA 92618
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
David D O'toole officer: CFO 1640 MARENGO STREET, LOS ANGELES CA 90033
Donna Shiroma officer: General Counsel C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Cary Guy Vance director 800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
Michael S Perry director, officer: Chief Executive Officer C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Suzanne Crowe director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Jan Stern Reed director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Michael Holder officer: Chief Financial Officer 6170 RESEARCH RD., STE 103, FRISCO TX 75034
Kathy M. Mcgee officer: Chief Operating Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Sean Ekins officer: Sr. VP of Finance C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
David Mcintyre officer: Chief Financial Officer SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Damien Mcdonald director 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Erin Liberto officer: Chief Commercial Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355